Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Bios Life has raised $25 million in seed funding to develop digital twins for cancer screening, led by Redmile, Vsquared Ventures, and Kindred Capital.
PRIVATEAug 11, 2026•about 4 hours ago
Amount Raised
$25 Million
Round Type
Seed
BostonBiotechnologyHealth CareMedical
Investors
Kindred CapitalVsquared VenturesRedmile
Description
Bios Life has emerged from stealth mode with $25 million in seed funding, aimed at developing digital twin cancer risk models. The funding round is led by Redmile, Vsquared Ventures, and Kindred Capital, marking the company's first outside funding. A multi-year partnership with Tempus complements its innovative approach to cancer screening. The company's technology seeks to address the significant gaps in access to tailored care for high-risk individuals and cancer survivors.
Company Information
Company
Bios Life
Location
Boston, Massachusetts, United States
About
Bios Life is a healthtech company focused on developing digital twin cancer risk models. Founded by former BioNTech executives, the company aims to provide tailored care for high-risk individuals and cancer survivors. Their platform incorporates clinical, lab, and genetic data to continuously update patient risk profiles. Bios Life has emerged from stealth with a significant funding round and partnerships to enhance its technology and services.
BostonBiotechnologyHealth CareMedical